For the quarter ending 2026-03-31, ARWR made $73,737K in revenue. -$132,732K in net income. Net profit margin of -180.01%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 73,737 | 264,033 | -26,266* | 27,767 |
| Research and development | 173,253 | 177,203 | 163,953* | 162,368 |
| General and administrative | - | 46,021 | 34,912* | 30,949 |
| Selling, general and administrative | 41,744 | - | - | - |
| Total operating expenses | 214,997 | 223,224 | 198,865* | 193,317 |
| Operating (gain) income | -141,260 | 40,809 | -225,131* | -165,550 |
| Interest income | 16,869 | 9,690 | 6,338* | 11,019 |
| Interest expense | 23,846 | 22,505 | 20,329* | 24,382 |
| Loss on equity method investment | -6,719 | - | - | - |
| Gain on vie's sale of ipr&d assets | 19,000 | - | - | - |
| Other, net | -1,609 | 277 | 4,866* | -176 |
| Total other income (expense) | 3,695 | -12,538 | -9,125* | -13,539 |
| (gain) income before income tax expense and noncontrolling interest | -137,565 | 28,271 | -234,257* | -179,089 |
| Income tax expense | 7 | 29 | 19,445* | -437 |
| Net (gain) income including noncontrolling interest | -137,572 | 28,242 | -253,702* | -178,652 |
| Net loss attributable to noncontrolling interest, net of tax | -4,840 | -2,569 | 40,735* | -3,411 |
| Net (loss) income attributable to arrowhead pharmaceuticals, inc | -132,732 | 30,811 | -294,437 | -175,241 |
| Basic EPS | -0.93 | 0.22 | -2.285 | -1.26 |
| Diluted EPS | -0.93 | 0.22 | -2.305 | -1.26 |
| Basic Average Shares | 142,417,000 | 137,039,000 | 128,872,000 | 139,039,000 |
| Diluted Average Shares | 142,417,000 | 140,706,000 | 127,751,000 | 139,039,000 |
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)